Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Elong Power Holding (NASDAQ:ELPW) Stock Analysis: Lithium Battery Pivot and Reverse Consolidation Strategy in March 2026

Elong Power Holding Limited (NASDAQ:ELPW) experienced a 24.14% stock price decline to $3.52 in March 2026, despite a subsequent 39% rally on March 13, 2026 reflecting the extreme volatility characterizing the microcap Chinese battery manufacturer. The company's execution of a dramatic 1-for-80 reverse share …

Team Kalkine | 17 March 2026

Ispire Technology (NASDAQ:ISPR) Rallies 33% Amid Strategic Pivot to Nicotine Sector and Cost Optimization

For investors seeking exposure to the vaping hardware sector with exposure to both nicotine and cannabis markets, ISPR represents an intriguing opportunity centered on business repositioning and operational restructuring. The company's strategic pivot away from struggling cannabis markets toward the larger, more stable nicotine …

Team Kalkine | 17 March 2026

Coffee Holding Company (NASDAQ:JVA) Surges ~30% on Favourable Fiscal 2025 Sales Growth and Dividend Support

For income-focused investors seeking exposure to the essential consumer goods sector with consistent profitability and attractive dividend yields, JVA represents a compelling opportunity. The company's decades-long history of successful operations through multiple market cycles, established brand portfolio, and integrated supply chain position the company …

Team Kalkine | 17 March 2026

LENSAR (NASDAQ:LNSR) Stock Analysis: Alcon Merger Termination and Standalone Strategy Shift in March 2026

The broader market context reveals heightened regulatory scrutiny of consolidation within specialized medical device sectors, particularly markets where a small number of competitors dominate. The FTC's determination that the merger would reduce competition and innovation in femtosecond laser-assisted cataract surgery (FLACS) systems demonstrates the …

Team Kalkine | 17 March 2026

CytomX (NASDAQ:CTMX)- Oncology Focus and Varseta-M Development Challenges

CytomX is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) based on its proprietary PROBODY platform technology, which uses conditional activation to improve drug selectivity and reduce off-target toxicity. The company is transitioning from a collaboration-focused model (with major partners including Bristol Myers Squibb, …

Team Kalkine | 17 March 2026

Digital Currency X Technology (NASDAQ:DCX) Stock Analysis: Recovery Play After Nasdaq Compliance Victory

The broader digital asset infrastructure sector remains in focus as institutional adoption accelerates in 2026. Digital Currency X has positioned itself at an interesting inflection point—resolving compliance concerns while building a substantial treasury. Understanding why DCX stock is moving today requires examining both the …

Team Kalkine | 17 March 2026

Dragonfly Energy (NASDAQ:DFLI)Turnaround Story Despite Market Headwinds

The lithium-ion battery manufacturer has emerged as a leader in the recreational vehicle and marine power systems market, with over 400,000 batteries sold to date. However, the RV industry's cyclical nature and economic headwinds have created near-term headwinds that have weighed on investor sentiment. …

Team Kalkine | 17 March 2026

Decent Holding (NASDAQ:DXST) Strategic Pivot and Recovery Potential in March 2026

The broader market context reveals heightened scrutiny of microcap stocks trading below $5.00 per share, particularly those with limited market liquidity and elevated short interest. DXST's situation exemplifies the challenges facing small-cap Chinese companies navigating regulatory requirements, capital constraints, and investor skepticism in 2026.

Team Kalkine | 17 March 2026

Edesa Biotech (NASDAQ:EDSA) Rallies 37% on Phase 3 Clinical Trial Progress and Insider Buying

For investors seeking exposure to innovative biopharmaceutical companies with potential breakthrough therapies, EDSA presents a compelling opportunity to invest in a company with near-term regulatory catalysts and multiple shots on goal across its pipeline. The company's focus on inflammatory and immune-related diseases addresses substantial …

Team Kalkine | 17 March 2026

Braiin (NASDAQ:BRAI) Stock Analysis: AI and Bitcoin Mining Infrastructure Play Surges

The convergence of AI adoption, labor market tightness, and willingness of enterprises to invest in automation creates compelling tailwinds for platform companies like Braiin. However, execution risk remains substantial as the company scales across diverse verticals. Understanding BRAI stock requires assessing both the technological …

Team Kalkine | 17 March 2026
Support

Hi! How can we help you today?

Loading…